Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: Clinical and angiographic safety profile

Marco Valgimigli, Gian Matteo Rigolin, Corrado Cittanti, Patrizia Malagutti, Salvatore Curello, Gianfranco Percoco, Anna Maria Bugli, Matteo Della Porta, Letizia Zenone Bragotti, Lucia Ansani, Endri Mauro, Arnalda Lanfranchi, Melchiore Giganti, Luciano Feggi, Gianluigi Castoldi, Roberto Ferrari

Research output: Contribution to journalArticle

208 Citations (Scopus)

Abstract

Aims: There is increasing evidence that stem cell (SC) mobilization to the heart and their differentiation into cardiac cells is a naturally occurring process. We sought to assess the safety and feasibility of granulocyte-colony stimulating factor (G-CSF) administration in humans to enhance SC mobilization and left ventricle (LV) injury repair during myocardial infarction (MI). Methods and results: Twenty patients with STEMI (mean age, 61 ± 10 years), of whom 14 were submitted to primary percutaneous coronary intervention, were randomized to G-CSF (5 μg/kg/day s.c. for 4 consecutive days) or placebo. At entry and then at months 3 and 6, 99mTc-sestamibi gated-SPECT was performed to estimate extension of perfusion defect (PD) and LV function. The study drug was well tolerated and induced a significant increase of white blood count, CD34+ cells, and CD34+ cells coexpressing AC133 and VEGFR-2. At follow-up, treated and placebo groups did not differ for the angiographic coronary late loss and showed a similar pattern of PD recovery, whereas in the former at 6 months LVEF and especially LVEDV tended to be relatively higher (P = 0.068) and lower (P = 0.054), respectively. Conclusion G-CSF administration in acute MI patients was feasible and did not lead to any clinical or angiographic adverse events and resulted in CD34+ and CD34+AC133+VEGFR2+ cell mobilization.

Original languageEnglish
Pages (from-to)1838-1845
Number of pages8
JournalEuropean Heart Journal
Volume26
Issue number18
DOIs
Publication statusPublished - Sep 2005

Fingerprint

Hematopoietic Stem Cell Mobilization
Granulocyte Colony-Stimulating Factor
Bone Marrow Cells
Myocardial Infarction
Safety
Heart Ventricles
Perfusion
Placebos
Technetium Tc 99m Sestamibi
Vascular Endothelial Growth Factor Receptor-2
Percutaneous Coronary Intervention
Single-Photon Emission-Computed Tomography
Leukocyte Count
Wounds and Injuries
Pharmaceutical Preparations

Keywords

  • CD34
  • Endothelial progenitor cells
  • Granulocyte-colony stimulating factor
  • Myocardial infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans : Clinical and angiographic safety profile. / Valgimigli, Marco; Rigolin, Gian Matteo; Cittanti, Corrado; Malagutti, Patrizia; Curello, Salvatore; Percoco, Gianfranco; Bugli, Anna Maria; Della Porta, Matteo; Bragotti, Letizia Zenone; Ansani, Lucia; Mauro, Endri; Lanfranchi, Arnalda; Giganti, Melchiore; Feggi, Luciano; Castoldi, Gianluigi; Ferrari, Roberto.

In: European Heart Journal, Vol. 26, No. 18, 09.2005, p. 1838-1845.

Research output: Contribution to journalArticle

Valgimigli, M, Rigolin, GM, Cittanti, C, Malagutti, P, Curello, S, Percoco, G, Bugli, AM, Della Porta, M, Bragotti, LZ, Ansani, L, Mauro, E, Lanfranchi, A, Giganti, M, Feggi, L, Castoldi, G & Ferrari, R 2005, 'Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: Clinical and angiographic safety profile', European Heart Journal, vol. 26, no. 18, pp. 1838-1845. https://doi.org/10.1093/eurheartj/ehi289
Valgimigli, Marco ; Rigolin, Gian Matteo ; Cittanti, Corrado ; Malagutti, Patrizia ; Curello, Salvatore ; Percoco, Gianfranco ; Bugli, Anna Maria ; Della Porta, Matteo ; Bragotti, Letizia Zenone ; Ansani, Lucia ; Mauro, Endri ; Lanfranchi, Arnalda ; Giganti, Melchiore ; Feggi, Luciano ; Castoldi, Gianluigi ; Ferrari, Roberto. / Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans : Clinical and angiographic safety profile. In: European Heart Journal. 2005 ; Vol. 26, No. 18. pp. 1838-1845.
@article{4602247306ee4332b7118e1e8de100b9,
title = "Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: Clinical and angiographic safety profile",
abstract = "Aims: There is increasing evidence that stem cell (SC) mobilization to the heart and their differentiation into cardiac cells is a naturally occurring process. We sought to assess the safety and feasibility of granulocyte-colony stimulating factor (G-CSF) administration in humans to enhance SC mobilization and left ventricle (LV) injury repair during myocardial infarction (MI). Methods and results: Twenty patients with STEMI (mean age, 61 ± 10 years), of whom 14 were submitted to primary percutaneous coronary intervention, were randomized to G-CSF (5 μg/kg/day s.c. for 4 consecutive days) or placebo. At entry and then at months 3 and 6, 99mTc-sestamibi gated-SPECT was performed to estimate extension of perfusion defect (PD) and LV function. The study drug was well tolerated and induced a significant increase of white blood count, CD34+ cells, and CD34+ cells coexpressing AC133 and VEGFR-2. At follow-up, treated and placebo groups did not differ for the angiographic coronary late loss and showed a similar pattern of PD recovery, whereas in the former at 6 months LVEF and especially LVEDV tended to be relatively higher (P = 0.068) and lower (P = 0.054), respectively. Conclusion G-CSF administration in acute MI patients was feasible and did not lead to any clinical or angiographic adverse events and resulted in CD34+ and CD34+AC133+VEGFR2+ cell mobilization.",
keywords = "CD34, Endothelial progenitor cells, Granulocyte-colony stimulating factor, Myocardial infarction",
author = "Marco Valgimigli and Rigolin, {Gian Matteo} and Corrado Cittanti and Patrizia Malagutti and Salvatore Curello and Gianfranco Percoco and Bugli, {Anna Maria} and {Della Porta}, Matteo and Bragotti, {Letizia Zenone} and Lucia Ansani and Endri Mauro and Arnalda Lanfranchi and Melchiore Giganti and Luciano Feggi and Gianluigi Castoldi and Roberto Ferrari",
year = "2005",
month = "9",
doi = "10.1093/eurheartj/ehi289",
language = "English",
volume = "26",
pages = "1838--1845",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "18",

}

TY - JOUR

T1 - Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans

T2 - Clinical and angiographic safety profile

AU - Valgimigli, Marco

AU - Rigolin, Gian Matteo

AU - Cittanti, Corrado

AU - Malagutti, Patrizia

AU - Curello, Salvatore

AU - Percoco, Gianfranco

AU - Bugli, Anna Maria

AU - Della Porta, Matteo

AU - Bragotti, Letizia Zenone

AU - Ansani, Lucia

AU - Mauro, Endri

AU - Lanfranchi, Arnalda

AU - Giganti, Melchiore

AU - Feggi, Luciano

AU - Castoldi, Gianluigi

AU - Ferrari, Roberto

PY - 2005/9

Y1 - 2005/9

N2 - Aims: There is increasing evidence that stem cell (SC) mobilization to the heart and their differentiation into cardiac cells is a naturally occurring process. We sought to assess the safety and feasibility of granulocyte-colony stimulating factor (G-CSF) administration in humans to enhance SC mobilization and left ventricle (LV) injury repair during myocardial infarction (MI). Methods and results: Twenty patients with STEMI (mean age, 61 ± 10 years), of whom 14 were submitted to primary percutaneous coronary intervention, were randomized to G-CSF (5 μg/kg/day s.c. for 4 consecutive days) or placebo. At entry and then at months 3 and 6, 99mTc-sestamibi gated-SPECT was performed to estimate extension of perfusion defect (PD) and LV function. The study drug was well tolerated and induced a significant increase of white blood count, CD34+ cells, and CD34+ cells coexpressing AC133 and VEGFR-2. At follow-up, treated and placebo groups did not differ for the angiographic coronary late loss and showed a similar pattern of PD recovery, whereas in the former at 6 months LVEF and especially LVEDV tended to be relatively higher (P = 0.068) and lower (P = 0.054), respectively. Conclusion G-CSF administration in acute MI patients was feasible and did not lead to any clinical or angiographic adverse events and resulted in CD34+ and CD34+AC133+VEGFR2+ cell mobilization.

AB - Aims: There is increasing evidence that stem cell (SC) mobilization to the heart and their differentiation into cardiac cells is a naturally occurring process. We sought to assess the safety and feasibility of granulocyte-colony stimulating factor (G-CSF) administration in humans to enhance SC mobilization and left ventricle (LV) injury repair during myocardial infarction (MI). Methods and results: Twenty patients with STEMI (mean age, 61 ± 10 years), of whom 14 were submitted to primary percutaneous coronary intervention, were randomized to G-CSF (5 μg/kg/day s.c. for 4 consecutive days) or placebo. At entry and then at months 3 and 6, 99mTc-sestamibi gated-SPECT was performed to estimate extension of perfusion defect (PD) and LV function. The study drug was well tolerated and induced a significant increase of white blood count, CD34+ cells, and CD34+ cells coexpressing AC133 and VEGFR-2. At follow-up, treated and placebo groups did not differ for the angiographic coronary late loss and showed a similar pattern of PD recovery, whereas in the former at 6 months LVEF and especially LVEDV tended to be relatively higher (P = 0.068) and lower (P = 0.054), respectively. Conclusion G-CSF administration in acute MI patients was feasible and did not lead to any clinical or angiographic adverse events and resulted in CD34+ and CD34+AC133+VEGFR2+ cell mobilization.

KW - CD34

KW - Endothelial progenitor cells

KW - Granulocyte-colony stimulating factor

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=24344446509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24344446509&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehi289

DO - 10.1093/eurheartj/ehi289

M3 - Article

C2 - 15860518

AN - SCOPUS:24344446509

VL - 26

SP - 1838

EP - 1845

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 18

ER -